Primary splenic angiosarcoma: a case series of a rare oncological entity and diagnostic challenge
Acta Oncol. 2024 Apr 15;63:192-197. doi: 10.2340/1651-226X.2023.35412.ABSTRACTBACKGROUND AND PURPOSE: Primary angiosarcoma of the spleen (PAS), an exceptionally rare and aggressive neoplasm with high metastatic risk (70%-85%), is frequently diagnosed in an advanced or metastatic stage. It presents diagnostic challenges due to its nonspecific symptomatology and resemblance to benign vascular lesions in various imaging modalities.PATIENTS AND METHODS: This case series aims to clarify the diagnostic difficulties by comparing imaging characteristics (CT-scan, MRI, and [18F]FDG-PET/CT) as well as pathological findings of three ...
Source: Acta Oncologica - April 15, 2024 Category: Cancer & Oncology Authors: Iris Dirven Philippe Leclercq Lionel D'Hondt Valentine Delmotte Pierre Lefesvre Hendrik Reynaert Frederik Vandenbroucke Magali Surmont Source Type: research
Primary splenic angiosarcoma: a case series of a rare oncological entity and diagnostic challenge
Acta Oncol. 2024 Apr 15;63:192-197. doi: 10.2340/1651-226X.2023.35412.ABSTRACTBACKGROUND AND PURPOSE: Primary angiosarcoma of the spleen (PAS), an exceptionally rare and aggressive neoplasm with high metastatic risk (70%-85%), is frequently diagnosed in an advanced or metastatic stage. It presents diagnostic challenges due to its nonspecific symptomatology and resemblance to benign vascular lesions in various imaging modalities.PATIENTS AND METHODS: This case series aims to clarify the diagnostic difficulties by comparing imaging characteristics (CT-scan, MRI, and [18F]FDG-PET/CT) as well as pathological findings of three ...
Source: Acta Oncologica - April 15, 2024 Category: Cancer & Oncology Authors: Iris Dirven Philippe Leclercq Lionel D'Hondt Valentine Delmotte Pierre Lefesvre Hendrik Reynaert Frederik Vandenbroucke Magali Surmont Source Type: research
Reducing renal function assessment prior to platinum-based chemotherapy: a real-world evaluation
Acta Oncol. 2024 Apr 10;63:169-174. doi: 10.2340/1651-226X.2024.23960.ABSTRACTBACKGROUND: Platinum-based chemotherapy, a widely used backbone of systemic cytotoxic anticancer treatment, is associated with nephrotoxicity. Currently, renal function is generally assessed prior to each administration of cisplatin or carboplatin, but there is no guideline regarding the frequency of renal function determination.OBJECTIVE: The primary objective was to determine the median time to a clinically relevant dosage adjustment (>10%) due to change in renal function in patients treated with cisplatin and carboplatin. Secondly, variable...
Source: Acta Oncologica - April 10, 2024 Category: Cancer & Oncology Authors: Suzanne Van der Gaag Mariette Labots Eleonora L Swart Mirjam Crul Source Type: research
Is the risk of ischemic heart disease in women after radiotherapy for breast cancer nowadays still (linearly) associated with the mean heart dose?
Acta Oncol. 2024 Apr 10;63:175-178. doi: 10.2340/1651-226X.2024.34751.NO ABSTRACTPMID:38597665 | DOI:10.2340/1651-226X.2024.34751 (Source: Acta Oncologica)
Source: Acta Oncologica - April 10, 2024 Category: Cancer & Oncology Authors: Henk Struikmans Anna Petoukhova Joop H M Schreur Mirjam E Mast Philip M Poortmans Source Type: research
Have the recent advancements in cancer therapy and survival benefitted patients of all age groups across the Nordic countries? NORDCAN survival analyses 2002-2021
Acta Oncol. 2024 Apr 10;63:179-191. doi: 10.2340/1651-226X.2024.35094.ABSTRACTBACKGROUND: Since the early 2000s, overall and site-specific cancer survival have improved substantially in the Nordic countries. We evaluated whether the improvements have been similar across countries, major cancer types, and age groups.MATERIAL AND METHODS: Using population-based data from the five Nordic cancer registries recorded in the NORDCAN database, we included a cohort of 1,525,854 men and 1,378,470 women diagnosed with cancer (except non-melanoma skin cancer) during 2002-2021, and followed for death until 2021. We estimated 5-year rel...
Source: Acta Oncologica - April 10, 2024 Category: Cancer & Oncology Authors: Anna L V Johansson Simon M K ønig Siri Lar ønningen Gerda Engholm Niels Kroman Karri Sepp ä Nea Malila Bjarni Á Steig Eva Maria Gudmundsd óttir El ínborg J Ólafsdóttir Frida E Lundberg Therese M-L Andersson Paul C Lambert Mats Lambe David Petterss Source Type: research
Reducing renal function assessment prior to platinum-based chemotherapy: a real-world evaluation
Acta Oncol. 2024 Apr 10;63:169-174. doi: 10.2340/1651-226X.2024.23960.ABSTRACTBACKGROUND: Platinum-based chemotherapy, a widely used backbone of systemic cytotoxic anticancer treatment, is associated with nephrotoxicity. Currently, renal function is generally assessed prior to each administration of cisplatin or carboplatin, but there is no guideline regarding the frequency of renal function determination.OBJECTIVE: The primary objective was to determine the median time to a clinically relevant dosage adjustment (>10%) due to change in renal function in patients treated with cisplatin and carboplatin. Secondly, variable...
Source: Acta Oncologica - April 10, 2024 Category: Cancer & Oncology Authors: Suzanne Van der Gaag Mariette Labots Eleonora L Swart Mirjam Crul Source Type: research
Is the risk of ischemic heart disease in women after radiotherapy for breast cancer nowadays still (linearly) associated with the mean heart dose?
Acta Oncol. 2024 Apr 10;63:175-178. doi: 10.2340/1651-226X.2024.34751.NO ABSTRACTPMID:38597665 | DOI:10.2340/1651-226X.2024.34751 (Source: Acta Oncologica)
Source: Acta Oncologica - April 10, 2024 Category: Cancer & Oncology Authors: Henk Struikmans Anna Petoukhova Joop H M Schreur Mirjam E Mast Philip M Poortmans Source Type: research
Have the recent advancements in cancer therapy and survival benefitted patients of all age groups across the Nordic countries? NORDCAN survival analyses 2002-2021
Acta Oncol. 2024 Apr 10;63:179-191. doi: 10.2340/1651-226X.2024.35094.ABSTRACTBACKGROUND: Since the early 2000s, overall and site-specific cancer survival have improved substantially in the Nordic countries. We evaluated whether the improvements have been similar across countries, major cancer types, and age groups.MATERIAL AND METHODS: Using population-based data from the five Nordic cancer registries recorded in the NORDCAN database, we included a cohort of 1,525,854 men and 1,378,470 women diagnosed with cancer (except non-melanoma skin cancer) during 2002-2021, and followed for death until 2021. We estimated 5-year rel...
Source: Acta Oncologica - April 10, 2024 Category: Cancer & Oncology Authors: Anna L V Johansson Simon M K ønig Siri Lar ønningen Gerda Engholm Niels Kroman Karri Sepp ä Nea Malila Bjarni Á Steig Eva Maria Gudmundsd óttir El ínborg J Ólafsdóttir Frida E Lundberg Therese M-L Andersson Paul C Lambert Mats Lambe David Petterss Source Type: research
Reducing renal function assessment prior to platinum-based chemotherapy: a real-world evaluation
Acta Oncol. 2024 Apr 10;63:169-174. doi: 10.2340/1651-226X.2024.23960.ABSTRACTBACKGROUND: Platinum-based chemotherapy, a widely used backbone of systemic cytotoxic anticancer treatment, is associated with nephrotoxicity. Currently, renal function is generally assessed prior to each administration of cisplatin or carboplatin, but there is no guideline regarding the frequency of renal function determination.OBJECTIVE: The primary objective was to determine the median time to a clinically relevant dosage adjustment (>10%) due to change in renal function in patients treated with cisplatin and carboplatin. Secondly, variable...
Source: Acta Oncologica - April 10, 2024 Category: Cancer & Oncology Authors: Suzanne Van der Gaag Mariette Labots Eleonora L Swart Mirjam Crul Source Type: research
Is the risk of ischemic heart disease in women after radiotherapy for breast cancer nowadays still (linearly) associated with the mean heart dose?
Acta Oncol. 2024 Apr 10;63:175-178. doi: 10.2340/1651-226X.2024.34751.NO ABSTRACTPMID:38597665 | DOI:10.2340/1651-226X.2024.34751 (Source: Acta Oncologica)
Source: Acta Oncologica - April 10, 2024 Category: Cancer & Oncology Authors: Henk Struikmans Anna Petoukhova Joop H M Schreur Mirjam E Mast Philip M Poortmans Source Type: research
Have the recent advancements in cancer therapy and survival benefitted patients of all age groups across the Nordic countries? NORDCAN survival analyses 2002-2021
Acta Oncol. 2024 Apr 10;63:179-191. doi: 10.2340/1651-226X.2024.35094.ABSTRACTBACKGROUND: Since the early 2000s, overall and site-specific cancer survival have improved substantially in the Nordic countries. We evaluated whether the improvements have been similar across countries, major cancer types, and age groups.MATERIAL AND METHODS: Using population-based data from the five Nordic cancer registries recorded in the NORDCAN database, we included a cohort of 1,525,854 men and 1,378,470 women diagnosed with cancer (except non-melanoma skin cancer) during 2002-2021, and followed for death until 2021. We estimated 5-year rel...
Source: Acta Oncologica - April 10, 2024 Category: Cancer & Oncology Authors: Anna L V Johansson Simon M K ønig Siri Lar ønningen Gerda Engholm Niels Kroman Karri Sepp ä Nea Malila Bjarni Á Steig Eva Maria Gudmundsd óttir El ínborg J Ólafsdóttir Frida E Lundberg Therese M-L Andersson Paul C Lambert Mats Lambe David Petterss Source Type: research
Reducing renal function assessment prior to platinum-based chemotherapy: a real-world evaluation
Acta Oncol. 2024 Apr 10;63:169-174. doi: 10.2340/1651-226X.2024.23960.ABSTRACTBACKGROUND: Platinum-based chemotherapy, a widely used backbone of systemic cytotoxic anticancer treatment, is associated with nephrotoxicity. Currently, renal function is generally assessed prior to each administration of cisplatin or carboplatin, but there is no guideline regarding the frequency of renal function determination.OBJECTIVE: The primary objective was to determine the median time to a clinically relevant dosage adjustment (>10%) due to change in renal function in patients treated with cisplatin and carboplatin. Secondly, variable...
Source: Acta Oncologica - April 10, 2024 Category: Cancer & Oncology Authors: Suzanne Van der Gaag Mariette Labots Eleonora L Swart Mirjam Crul Source Type: research
Is the risk of ischemic heart disease in women after radiotherapy for breast cancer nowadays still (linearly) associated with the mean heart dose?
Acta Oncol. 2024 Apr 10;63:175-178. doi: 10.2340/1651-226X.2024.34751.NO ABSTRACTPMID:38597665 | DOI:10.2340/1651-226X.2024.34751 (Source: Acta Oncologica)
Source: Acta Oncologica - April 10, 2024 Category: Cancer & Oncology Authors: Henk Struikmans Anna Petoukhova Joop H M Schreur Mirjam E Mast Philip M Poortmans Source Type: research
Have the recent advancements in cancer therapy and survival benefitted patients of all age groups across the Nordic countries? NORDCAN survival analyses 2002-2021
Acta Oncol. 2024 Apr 10;63:179-191. doi: 10.2340/1651-226X.2024.35094.ABSTRACTBACKGROUND: Since the early 2000s, overall and site-specific cancer survival have improved substantially in the Nordic countries. We evaluated whether the improvements have been similar across countries, major cancer types, and age groups.MATERIAL AND METHODS: Using population-based data from the five Nordic cancer registries recorded in the NORDCAN database, we included a cohort of 1,525,854 men and 1,378,470 women diagnosed with cancer (except non-melanoma skin cancer) during 2002-2021, and followed for death until 2021. We estimated 5-year rel...
Source: Acta Oncologica - April 10, 2024 Category: Cancer & Oncology Authors: Anna L V Johansson Simon M K ønig Siri Lar ønningen Gerda Engholm Niels Kroman Karri Sepp ä Nea Malila Bjarni Á Steig Eva Maria Gudmundsd óttir El ínborg J Ólafsdóttir Frida E Lundberg Therese M-L Andersson Paul C Lambert Mats Lambe David Petterss Source Type: research
Cardiovascular events among patients with prostate cancer treated with abiraterone and enzalutamide
This study provides real-world evidence of the cardiovascular risk of AA and ENZ that may not appear in clinical trial settings. Adjusting for age, baseline comorbidities, and SES, the likelihood of a cardiovascular event did not differ between treatment groups.PMID:38591349 | DOI:10.2340/1651-226X.2024.20337 (Source: Acta Oncologica)
Source: Acta Oncologica - April 9, 2024 Category: Cancer & Oncology Authors: Onur Baser Gabriela Samayoa Archana Dwivedi Sara AlSaleh Burhan Cigdem Erdi Kizilkaya Source Type: research
